Skip to main content

Home/ Cancer/ Group items tagged kinase

Rss Feed Group items tagged

Matti Narkia

Cancer Journal: Latest cancer research Link between cancer and dietary restriction | ec... - 0 views

  •  
    A signalling pathway that influences how sensitive cancer cells are to the beneficial effects of dietary restriction is described in this week's Nature. Dietary restriction - eating less calories while maintaining essential vitamins and minerals - can extend lifespan, and reduce cancer incidence and growth. But some types of cancer cell are more sensitive to the anti-growth effects of dietary restriction than others, Nada Kalaany and David Sabatini report. The effect hinges on the activity of the phosphatidylinositol-3-kinase (PI3K) pathway. If the pathway is active, dietary restriction has no effect on cancer cells. However, if the pathway is inactive, tumours are sensitive to dietary restriction.
Matti Narkia

Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxyg... - 0 views

  •  
    Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM. Clin Cancer Res. 2004 Sep 1;10(17):5930-9. PMID: 15355926
Matti Narkia

Compound found in beans, nuts and cereals beats cancer (inositol pentakisphosphate) - 0 views

  •  
    A collaborative study led by UCL (University College London) shows that the compound - inositol pentakisphosphate - found in beans, nuts and cereals inhibits a key enzyme (phosphoinositide 3-kinase) involved in tumour growth. The findings, published in the latest issue of Cancer Research, suggest that a diet enriched in such foods could help prevent cancer, while the inhibitor offers a new tool for anti-cancer therapy.
Matti Narkia

Berberine Inhibits Metastasis of Nasopharyngeal Carcinoma 5-8F Cells by Targeting Rho K... - 0 views

  •  
    Berberine inhibits metastasis of nasopharyngeal carcinoma 5-8F cells by targeting Rho kinase-mediated Ezrin phosphorylation at threonine 567. Tang F, Wang D, Duan C, Huang D, Wu Y, Chen Y, Wang W, Xie C, Meng J, Wang L, Wu B, Liu S, Tian D, Zhu F, He Z, Deng F, Cao Y. J Biol Chem. 2009 Oct 2;284(40):27456-66. Epub 2009 Aug 3. PMID: 19651779
Matti Narkia

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer - British J... - 1 views

  •  
    Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Michelakis ED, Webster L, Mackey JR. Br J Cancer. 2008 Oct 7;99(7):989-94. Epub 2008 Sep 2. Review. PMID: 18766181 doi:10.1038/sj.bjc.6604554 The unique metabolism of most solid tumours (aerobic glycolysis, i.e., Warburg effect) is not only the basis of diagnosing cancer with metabolic imaging but might also be associated with the resistance to apoptosis that characterises cancer. The glycolytic phenotype in cancer appears to be the common denominator of diverse molecular abnormalities in cancer and may be associated with a (potentially reversible) suppression of mitochondrial function. The generic drug dichloroacetate is an orally available small molecule that, by inhibiting the pyruvate dehydrogenase kinase, increases the flux of pyruvate into the mitochondria, promoting glucose oxidation over glycolysis. This reverses the suppressed mitochondrial apoptosis in cancer and results in suppression of tumour growth in vitro and in vivo. Here, we review the scientific and clinical rationale supporting the rapid translation of this promising metabolic modulator in early-phase cancer clinical trials More than 40 nonrandomised trials of DCA in small cohorts of patients have been reported, but the first two randomised control trials of chronic oral therapy with DCA in congenital mitochondrial diseases were reported in 2006. In the first, a blinded placebo-controlled study was performed with oral DCA administered at 25 mg kg-1 day-1 in 30 patients with MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) (Kaufmann et al, 2006). Most patients enrolled in the DCA arm developed symptomatic peripheral neuropathy, compared with 4 out of 15 in the placebo arm, leading to the termination of the study. Seventeen out of 19 patients had at least partial resolution of peripheral neurological symptoms by 9 months after discontinuation of DCA. This neurotoxicity res
Matti Narkia

Green Beans for Cancer Prevention and Treatment. ( It is well known that eating green v... - 0 views

  •  
    It is well known that eating green vegetables, beans, nuts, cereals and fruits prevents cancer, now it is found that beans and wheat bran contains an enzyme inhibitor Inositol // pentakisphosphate which is found to have anti-cancer effects by blocking the action of enzyme Phosphoinositide 3 kinase.
Matti Narkia

Access : Tumours with PI3K activation are resistant to dietary restriction : Nature - 0 views

  •  
    Tumours with PI3K activation are resistant to dietary restriction. Nada Y. Kalaany & David M. Sabatini Nature. Published online 11 March 2009 doi:10.1038/nature07782
Matti Narkia

'Eat More Beans' to Stop Cancer - BBC NEWS | Health - 0 views

  •  
    Dr Marco Falasca and colleagues have discovered that a natural compound, called inositol pentakisphosphate, which is found in most legumes as well as in wheat bran and nuts, blocks the activity of the enzyme. When they tested its action in mice with ovarian and lung cancer they found it not only blocked tumour growth but also enhanced the effect of other cancer-killing drug
Matti Narkia

Factors Associated With Clinical Benefit From Epidermal Growth Factor Receptor Inhibito... - 0 views

  •  
    Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE. Oral Oncol. 2009 Oct;45(10):e155-60. Epub 2009 Jul 7. PMID: 19586795
1 - 9 of 9
Showing 20 items per page